Efficacy
DISEASE
Thirteen out of 30 patients who underwent RC achieved pT0N0M0, resulting in a pCR rate of 43.3% (95% CI, 25.5 to 62.6). At the time of cystectomy, 16 patients achieved < pT2N0M0, with a pathologic downstaging rate of 53.3% (95% CI, 34.3 to 71.7), and none of the patients had disease upstaging (Table Pathologic assessment at the time of radical cystectomy (After a median follow‐up of 11.0 months (data cut‐off on June 30, 2022), the median EFS and median OS for 30 evaluable patients have not been reached. One‐year EFS and OS rates were 79.2% and 81.7%, respectively (Figure Event‐free survival and overall survival in 30 evaluable patients.Event‐free survival and overall survival in 30 evaluable patients stratified by pathological response (pathologic complete response [pCR] vs non‐pCR).Among the 8 patients who did not undergo RC per willingness, the post‐treatment imaging evaluation showed that five patients achieved complete response, one patient achieved partial response, one patient had progressive disease, and one patient was not evaluable. These patients did not undergo repeat cystoscopy.